Published: Fall 2014
Making it the most common chronic bloodborne infection in the US, an estimated 3.2 million people are impacted by the Hepatitis C virus (HCV). Many are concerned about the approved HCV medications and high-cost therapies. To better understand the benefit implications of HCV, it is important to grasp the risk factors and clinical course of this infection.
Through education programs, benchmarking surveys and networking opportunities, members can REALIZE their potential to implement cutting-edge benefit strategies.
With our collective strategy programs, members’ unique strategies are MAXIMIZED through the use of group purchasing solutions.
Data analytics and advisor solutions help plan sponsors ADVANCE their benefit strategies and organizational performance.
Plan sponsors can ACCELERATE their strategies to deliver comprehensive health benefits through a trusted team of advisors encouraging a culture of health.